Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PD-1 inhibitor monotherapy
10 evidence topics · 7 sources
FDA-approved first-line indication: pembrolizumab as a single agent
KEYNOTE-048 design, stratification, and population
KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups
| Endpoint | CPS ≥1 | CPS ≥20 |
|---|---|---|
| Participants, pembrolizumab 200 mg every 3 weeks | “n=257” | “n=133” |
| Participants, cetuximab with platinum and FU | “n=255” | “n=122” |
| Median OS, pembrolizumab, months (95% CI) | “12.3 (10.8, 14.9)” | “14.9 (11.6, 21.5)” |
| Median OS, cetuximab with platinum and FU, months (95% CI) | “10.3 (9.0, 11.5)” | “10.7 (8.8, 12.8)” |
| OS hazard ratio (95% CI) | “0.78 (0.64, 0.96)” | “0.61 (0.45, 0.83)” |
| Median PFS, pembrolizumab, months (95% CI) | “3.2 (2.2, 3.4)” | “3.4 (3.2, 3.8)” |
| Median PFS, cetuximab with platinum and FU, months (95% CI) | “5.0 (4.8, 5.8)” | “5.0 (4.8, 6.2)” |
| PFS hazard ratio (95% CI) | “1.15 (0.95, 1.38)” | “0.97 (0.74, 1.27)” |
| ORR, pembrolizumab (95% CI) | “19% (14.5, 24.4)” | “23% (16.4, 31.4)” |
| ORR, cetuximab with platinum and FU (95% CI) | “35% (29.1, 41.1)” | “36% (27.6, 45.3)” |
| Median duration of response, pembrolizumab, months (range) | “20.9 (1.5+, 34.8+)” | “20.9 (2.7, 34.8+)” |
| Median duration of response, cetuximab with platinum and FU, months (range) | “4.5 (1.2+, 28.6+)” | “4.2 (1.2+, 22.3+)” |
KEYNOTE-048 pembrolizumab monotherapy: final analysis and the CPS 1-19 subgroup
KEYNOTE-048 primary publication: pembrolizumab monotherapy overall survival
“Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 four-year follow-up: pembrolizumab monotherapy
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 five-year follow-up: pembrolizumab monotherapy
“Median OS remained longer for pembrolizumab versus EXTREME in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 (HR, 0.61; 95 % CI, 0.46-0.81) and CPS ≥ 1 populations (HR, 0.74; 95 % CI, 0.61-0.89), and similar in the total population (HR, 0.82; 95 % CI, 0.69-0.97).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab monotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1
“For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the PD-L1 CPS < 1 subgroup, the ORR was 4.5% (n = 2; 95% CI, 0.6 to 15.5) for pembrolizumab versus 42.2% (n = 19; 95% CI, 27.7 to 57.8) for cetuximab-chemotherapy (Table 2 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the PD-L1 CPS 1-19 subgroup, the ORR was 14.5% (n = 18; 95% CI, 8.8 to 22.0) for pembrolizumab versus 33.8% (n = 45; 95% CI, 25.9 to 42.5) for cetuximab-chemotherapy (Table 2 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy outcomes for the PD-L1 CPS < 1 and CPS 1-19 subgroups (OS, PFS, and ORR) were not prespecified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote